<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="423">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02054208</url>
  </required_header>
  <id_info>
    <org_study_id>MP-CR-010</org_study_id>
    <nct_id>NCT02054208</nct_id>
  </id_info>
  <brief_title>Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease</brief_title>
  <official_title>A Double-blind, Single-center, Phase 1/2a Clinical Trial to Evaluate the Safety and Exploratory Efficacy of Intraventricular Administrations of NEUROSTEM® Versus Placebo Via an Ommaya Reservoir in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medipost Co Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medipost Co Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This combined phase 1/2a clinical trial is to investigate the safety, dose limiting toxicity&#xD;
      (DLT), and exploratory efficacy of three repeated intraventricular administrations of&#xD;
      NEUROSTEM® (human umbilical cord blood-derived mesenchymal stem cells) versus placebo via an&#xD;
      Ommaya reservoir at 4 week intervals in patients with Alzheimer's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is divided into the 2 stages: dose-escalation in stage 1 and randomized and&#xD;
      multiple-dose cohort parallel design in stage 2.The target population for enrollment in this&#xD;
      study is patients with mild to moderate Alzheimer's disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Stage 1: 9 subjects (3 subjects for low dose and 6 subjects for high dose) Stage 2: 36 subjects ( 24 subjects for high dose and 12 subjects for placebo) A total of 45 subjects to be enrolled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>24 weeks after the first dose</time_frame>
    <description>Number of subjects with adverse event, number of subjects with normal range of vital signs, mixed lymphocyte reaction result, and laboratory examination result</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from the baseline in ADAS-Cog</measure>
    <time_frame>24 weeks after the first dose</time_frame>
    <description>Alzheimer's Disease assessment Scale-Cognitive Subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from the baseline in S-IADL</measure>
    <time_frame>24 weeks after the first dose</time_frame>
    <description>Seoul Instrumental Activities of Daily Living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from the baseline in K-MMSE</measure>
    <time_frame>24 weeks after the first dose</time_frame>
    <description>Mini Mental State Exmination Korean version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from the baseline in CGA-NPI</measure>
    <time_frame>24 weeks from the first dose</time_frame>
    <description>Caregiver-administered Neuropsychiatric Inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADAS-Cog Response Rate</measure>
    <time_frame>24 weeks after the first dose</time_frame>
    <description>ADAS-cog response is defined as no worsening (no change or improvement on ADAS-cog score) of the ADAS-cog score at 24 weeks after the first administration compared to the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CDR-SOB</measure>
    <time_frame>24 weeks after the first dose</time_frame>
    <description>Clinical Dementia Rating-Sum of Box</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Florbetaben-PET</measure>
    <time_frame>24 weeks after the first dose</time_frame>
    <description>Florbetaben - Pittsburgh Compound B-positron emission tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FDG-PET (CMRglc: regional cerebral metabolic rate for glucose)</measure>
    <time_frame>24 weeks after the first dose</time_frame>
    <description>fluorodeoxyglucose positron emission tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CIBIC-plus</measure>
    <time_frame>24 weeks after the first dose</time_frame>
    <description>The Clinician's Interview Based Impression of Change-plus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in MRI (DTI mapping)</measure>
    <time_frame>24 weeks after the first dose</time_frame>
    <description>MRI Analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from the baseline in CSF biomarkers</measure>
    <time_frame>24 weeks after the first dose</time_frame>
    <description>biomakrer analysis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>NEUROSTEM (hUCB-MSCs)- low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>human umbilical cord blood derived mesenchymal stem cells Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NEUROSTEM (hUCB-MSCs) - high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>human umbilical cord blood derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline 2mL, doses separated by 4 weeks for a total of 3 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human umbilical cord blood derived mesenchymal stem cells</intervention_name>
    <description>Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals&#xD;
High dose: 3 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals</description>
    <arm_group_label>NEUROSTEM (hUCB-MSCs) - high dose</arm_group_label>
    <arm_group_label>NEUROSTEM (hUCB-MSCs)- low dose</arm_group_label>
    <other_name>NEUROSTEM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal saline 2mL</intervention_name>
    <description>Intraventricular administrations of 2mL Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1 stage Inclusion Criteria:&#xD;
&#xD;
          1. Korean male or female at 50 -85 years of age&#xD;
&#xD;
          2. Diagnosis of Probable Alzheimer type according to NINCDS-ADRDA criteria at Visit 1&#xD;
             (Screening)&#xD;
&#xD;
          3. Korea Mini-Mental State Examination (KMMSE) score of 18 - 26 at Visit 1 (Screening)&#xD;
&#xD;
          4. Positive for Amyloid on PIB-PET or Florbetaben PET&#xD;
&#xD;
          5. A subject who is informed of the clinical trial and signs a consent form (if unable to&#xD;
             sign, a consent from a legally acceptable representative is required)&#xD;
&#xD;
        2 stage Inclusion Criteria:&#xD;
&#xD;
          1. Korean male or female at 50 -85 years of age&#xD;
&#xD;
          2. Diagnosis of Probable Alzheimer type or mild cognitive impairment due to Alzheimer's&#xD;
             disease (stage A) according to NIA-AA criteria at Visit 1(Screening)&#xD;
&#xD;
          3. Korea Mini-Mental State Examination (KMMSE) score of over 18 at Visit 1 (Screening)&#xD;
&#xD;
          4. Positive for Amyloid on Florbetaben PET&#xD;
&#xD;
          5. A subject with neurodegeneration (mild atrophy of the brain) as confirmed by MRI&#xD;
&#xD;
          6. A subject who is informed of the clinical trial and signs a consent form (if unable to&#xD;
             sign, a consent from a legally acceptable representative is required)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concurrent mental disorder (such as schizophrenia, depression, bi-polar diseases or&#xD;
             others) aside from dementia&#xD;
&#xD;
          2. Concurrent dementia as a result of other neurodegenerative disorders (due to&#xD;
             infectious disease of the central nervous system such as HIV, syphilis), head injury,&#xD;
             Creutzfeld-Jacob disease, Pick's disease, Huntington's disease, or Parkinson's disease&#xD;
&#xD;
          3. Diagnosis of severe white matter hyperintensitivity (WMH) according to CREDOS&#xD;
             (Clinical REsearch Center for Dementia of South Korea), which is defined as ≥ 25mm of&#xD;
             the deep white matter and ≥ 10mm of the periventricular capping/banding in lengths&#xD;
&#xD;
          4. History of stroke within 3 months prior to study enrollment&#xD;
&#xD;
          5. Severe liver disorder (equivalent to double the normal values of ALT and AST) at Visit&#xD;
             1&#xD;
&#xD;
          6. Severe kidney disorder (serum creatinine ≥1.5mg/dL) at Visit 1&#xD;
&#xD;
          7. Pregnant or lactating females&#xD;
&#xD;
          8. Abnormal Laboratory findings at Visit 1&#xD;
&#xD;
               -  Hemoglobin &lt; 9.5 g/dL for male and &lt;9.0 g/dL for female&#xD;
&#xD;
               -  Total WBC Count &lt; 3000/mm3&#xD;
&#xD;
               -  Total Bilirubin &gt;= 3 mg/dL&#xD;
&#xD;
          9. Suspected active lung disease based on chest X-ray at Visit 1&#xD;
&#xD;
         10. Woman of childbearing age who refuses to practice medically acceptable contraceptive&#xD;
             method (post menopausal patient with no menstruation for at least 12 months is&#xD;
             considered as infertile)&#xD;
&#xD;
         11. History of screening failure for the clinical trial of NEUROSTEM® in the past 6 months&#xD;
&#xD;
         12. Participation in another clinical trial in the past 3 months prior to the beginning&#xD;
             (Week 0) of this clinical trial&#xD;
&#xD;
         13. Bleeding disorder (abnormal blood coagulation test result (i.e. platelet count of &lt;&#xD;
             150,000/mm3, PT ≥ 1.5 INR, or aPTT ≥ 1.5 x control anti-coagulant or anti-platelet,&#xD;
             without anticoagulant or anti-platelet therapy)&#xD;
&#xD;
         14. Diagnosis of cancer (of any body system, including brain tumor)&#xD;
&#xD;
         15. Substance/alcohol abuse&#xD;
&#xD;
         16. Contraindicated for any of the tests performed during the clinical trial period (for&#xD;
             example, MRI, CT, PET)&#xD;
&#xD;
         17. A subject in whom Ommaya reservoir insertion is considered difficult&#xD;
&#xD;
         18. Whom the principal investigator considers inappropriate for participation in the study&#xD;
             due to any reasons other than those listed above&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wonil Oh, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medipost Co Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.gov/ct2/show/NCT01297218?term=neurostem&amp;rank=2</url>
    <description>first-in-man study of NEUROSTEM</description>
  </link>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>January 29, 2014</study_first_submitted>
  <study_first_submitted_qc>February 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>human umbilical cord blood derived mesenchymal stem cells</keyword>
  <keyword>stem cells</keyword>
  <keyword>alzheimer's disease</keyword>
  <keyword>cognitive ability</keyword>
  <keyword>mesenchymal stem cells</keyword>
  <keyword>cord blood</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

